These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38101152)

  • 1. Cost-Effectiveness of Comprehensive Genomic Profiling in Patients With Non-Small Cell Lung Cancer for the Colombian Health System.
    Gamboa O; Bonilla CE; Quitian D; Torres GF; Buitrago G; Cardona AF
    Value Health Reg Issues; 2024 Jan; 39():115-125. PubMed ID: 38101152
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma.
    Dong OM; Poonnen PJ; Winski D; Reed SD; Vashistha V; Bates J; Kelley MJ; Voora D
    Value Health; 2022 Apr; 25(4):582-594. PubMed ID: 35365302
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrating comprehensive genomic sequencing of non-small cell lung cancer into a public healthcare system.
    Perdrizet K; Stockley TL; Law JH; Smith A; Zhang T; Fernandes R; Shabir M; Sabatini P; Youssef NA; Ishu C; Li JJ; Tsao MS; Pal P; Cabanero M; Schwock J; Ko HM; Boerner S; Ruff H; Shepherd FA; Bradbury PA; Liu G; Sacher AG; Leighl NB
    Cancer Treat Res Commun; 2022; 31():100534. PubMed ID: 35278845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
    Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
    Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer.
    Signorovitch J; Zhou Z; Ryan J; Anhorn R; Chawla A
    J Med Econ; 2019 Feb; 22(2):140-150. PubMed ID: 30430885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Budget Impact Analysis of Comprehensive Genomic Profiling in Advanced Non-Small Cell Lung Cancer in Taiwan.
    Tsai YL; Chang CJ
    Value Health Reg Issues; 2023 May; 35():48-56. PubMed ID: 36863067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective.
    Tan PT; Aziz MIA; Pearce F; Lim WT; Wu DB; Ng K
    BMC Cancer; 2018 Mar; 18(1):352. PubMed ID: 29587666
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost-effectiveness of brigatinib in adult patients with ALK inhibitor-naive ALK-positive non-small cell lung cancer from a US perspective.
    Cranmer H; Kearns I; Young M; Humphries MJ; Trueman D
    J Manag Care Spec Pharm; 2022 Sep; 28(9):970-979. PubMed ID: 36001099
    [No Abstract]   [Full Text] [Related]  

  • 9. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
    Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
    J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of ceritinib in previously untreated anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer in the United States.
    Zhou ZY; Mutebi A; Han S; Bensimon AG; Louise Ricculli M; Xie J; Dalal A; Culver K
    J Med Econ; 2018 Jun; 21(6):577-586. PubMed ID: 29458286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
    Beca JM; Walsh S; Raza K; Hubay S; Robinson A; Mow E; Keech J; Chan KKW
    BMC Cancer; 2021 Oct; 21(1):1162. PubMed ID: 34715804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-Utility of a Prognostic Test Guiding Adjuvant Chemotherapy Decisions in Early-Stage Non-Small Cell Lung Cancer.
    Stenehjem DD; Bellows BK; Yager KM; Jones J; Kaldate R; Siebert U; Brixner DI
    Oncologist; 2016 Feb; 21(2):196-204. PubMed ID: 26614710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Budget impact analysis of comprehensive genomic profiling for untreated advanced or recurrent solid cancers in Japan.
    Tang W; Hanada K; Motoo Y; Sakamaki H; Oda T; Furuta K; Abutani H; Ito S; Tsutani K
    J Med Econ; 2023; 26(1):614-626. PubMed ID: 37073487
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
    Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
    J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer.
    Bertranou E; Bodnar C; Dansk V; Greystoke A; Large S; Dyer M
    J Med Econ; 2018 Feb; 21(2):113-121. PubMed ID: 28880737
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
    Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
    Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of nivolumab plus ipilimumab versus platinum-doublet chemotherapy for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
    Berling M; Chaudhary MA; Yuan Y; Varol N; Dale P; Testa E; Klint J; Lee A; Lubinga SJ; Penrod JR
    J Med Econ; 2022; 25(1):703-711. PubMed ID: 35659172
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of immune checkpoint inhibitors in the treatment of non-small-cell lung cancer as a second line in Taiwan.
    Leung JH; Chang CW; Chan AL; Lang HC
    Future Oncol; 2022 Mar; 18(7):859-870. PubMed ID: 35105168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
    Han J; Tian K; Yang J; Gong Y
    Lung Cancer; 2020 Aug; 146():42-49. PubMed ID: 32512272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.